INT103878

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 6.22
Pain Relevance 7.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (PTGDR) signal transducer activity (PTGDR)
Anatomy Link Frequency
basal ganglia 2
liver 1
putamen 1
striatum 1
epidermis 1
PTGDR (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 255 100.00 Very High Very High Very High
Nucleus accumbens 58 100.00 Very High Very High Very High
Dopamine 139 99.74 Very High Very High Very High
antagonist 17 99.44 Very High Very High Very High
Opioid 13 98.92 Very High Very High Very High
imagery 66 98.16 Very High Very High Very High
fluoxetine 12 97.48 Very High Very High Very High
agonist 42 96.92 Very High Very High Very High
opioid receptor 3 96.60 Very High Very High Very High
rapifen 12 95.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 314 100.00 Very High Very High Very High
Increased Venous Pressure Under Development 84 98.94 Very High Very High Very High
Anxiety Disorder 180 98.44 Very High Very High Very High
Restless Legs Syndrome 20 95.12 Very High Very High Very High
Rhinitis 2 94.40 High High
Tics 2 91.24 High High
Hyperalgesia 8 90.00 High High
Diabetes Mellitus 10 86.76 High High
Obesity 6 84.48 Quite High
Vomiting 4 83.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Striatal and thalamic D2-receptor binding was measured at baseline, after a single oral dose (20 mg) of fluoxetine, and after repeated dosing (2 wk, 20 mg/d).
D2-receptor Binding (binding) of associated with fluoxetine
1) Confidence 0.48 Published 2004 Journal Int. J. Neuropsychopharmacol. Section Abstract Doc Link 15315717 Disease Relevance 0 Pain Relevance 0.99
D2 receptor binding was determined by using [(11)C]raclopride as radioligand.
D2 receptor Binding (binding) of
2) Confidence 0.24 Published 2002 Journal Synapse Section Abstract Doc Link 12112410 Disease Relevance 0.13 Pain Relevance 0.79
In Langerhans cells of the epidermis this binding induces the formation of PDG2 which then binds to a specific receptor (prostaglandin-D2-receptor-1).
prostaglandin-D2-receptor-1 Binding (binds) of in epidermis
3) Confidence 0.19 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788595 Disease Relevance 1.03 Pain Relevance 0.21
Since the flush induced by niacin is primarily mediated through the interaction of prostaglandin D2 with a specific receptor (prostaglandin-D2-receptor-1) a selective antagonist of this receptor was developed (MK-0524, laropiprant).38,39 Laropiprant was initially developed as a treatment for allergic rhinitis.39,40 It is eliminated primarily after glucuronidation through the liver.41 A small part of laropiprant is metabolized through cytochromP450 3A4.
prostaglandin-D2-receptor-1 Binding (interaction) of in liver associated with rhinitis, antagonist and increased venous pressure under development
4) Confidence 0.14 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788595 Disease Relevance 0.74 Pain Relevance 0.05
Opioids may produce changes in the BG including increases in D2 receptor binding [88].
D2 receptor Binding (binding) of associated with opioid
5) Confidence 0.11 Published 2010 Journal Mol Pain Section Body Doc Link PMC2883978 Disease Relevance 0.41 Pain Relevance 1.81
The results of analysis by PET and SPECT studies of striatal D2 receptor binding in humans are inconclusive.
D2 receptor Binding (binding) of
6) Confidence 0.08 Published 2009 Journal Brain Nerve Section Abstract Doc Link 19514512 Disease Relevance 0.96 Pain Relevance 0.31
Others have suggested differential processing of pain within the BG - a more dorsal DA D2 receptor-mediated neurotransmission in the caudate and putamen that correlates with subjective ratings of sensory and affective qualities of the pain, along with a more ventral system involving the NAc, is associated with emotional processing [135].
D2 receptor Binding (associated) of in putamen associated with nucleus accumbens and pain
7) Confidence 0.07 Published 2010 Journal Mol Pain Section Body Doc Link PMC2883978 Disease Relevance 1.19 Pain Relevance 1.58
Second, a disturbance in dopaminergic function seems to be observed in OCD, as supported by recent neuroimaging studies showing an increase in dopamine transporter binding along with lowered levels of dopaminergic D2 receptor binding in the basal ganglia of patients with OCD (Kim et al 2003; Denys et al 2004).
D2 receptor Binding (binding) of in basal ganglia associated with dopamine and anxiety disorder
8) Confidence 0.03 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2416754 Disease Relevance 0.59 Pain Relevance 0.47
Second, a disturbance in dopaminergic function seems to be observed in OCD, as supported by recent neuroimaging studies showing an increase in dopamine transporter binding along with lowered levels of dopaminergic D2 receptor binding in the basal ganglia of patients with OCD (Kim et al 2003; Denys et al 2004).
D2 receptor Binding (binding) of in basal ganglia associated with dopamine and anxiety disorder
9) Confidence 0.02 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2416754 Disease Relevance 0.65 Pain Relevance 0.48
In fact, the DA system undergoes extensive maturation and rearrangement until early adulthood: for example, DA innervation of terminal areas, such as the prefrontal cortex is not completed until late adolescence in the rat [168]; a reduced basal levels of DA and a reduced pool of readily releasable DA have been reported in adolescent rats [192]; D1 and D2 receptor binding in the striatum undergoes robust changes during adolescence as a consequence of extensive pruning of DA synapses [199].
D2 receptor Binding (binding) of in striatum associated with dopamine
10) Confidence 0.01 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644494 Disease Relevance 0.51 Pain Relevance 0.54

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox